ORGO Q3 2022 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M+2.7% YoY

Gross Profit

$91M77.6% margin

Operating Income

$2M1.5% margin

Net Income

$215,0000.2% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-3.7%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$457M

Total Liabilities

$201M

Stockholders' Equity

$256M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$114M	+2.7%
Gross Profit	$91M	$88M	+3.5%
Operating Income	$2M	$16M	-89.1%
Net Income	$215,000	$13M	-98.3%

Revenue Segments

Advanced Wound care

$110M94%

Surgical and Sports Medicine

$7M6%